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The relaxin family of peptide hormones and their cognate GPCRs are becoming physiologically well-characterized in the cardio-
vascular system and particularly in female reproductive processes. Much less is known about the physiology and pharmacology of
these peptides in male reproduction, particularly as regards humans. H2-relaxin is involved in prostate function and growth, while
insulin-like peptide 3 (INSL3) is a major product of the testicular Leydig cells and, in the adult, appears to modulate steroido-
genesis and germ cell survival. In the fetus, INSL3 is a key hormone expressed shortly after sex determination and is responsible for
the ﬁrst transabdominal phase of testicular descent. Importantly, INSL3 is becoming a very useful constitutive biomarker reﬂecting
both fetal and post-natal development. Nothing is known about roles for INSL4 in male reproduction and only very little about
relaxin-3, which is mostly considered as a brain peptide, or INSL5. The former is expressed at very low levels in the testes, but has
no known physiology there, whereas the INSL5 knockout mouse does exhibit a testicular phenotype with mild effects on sper-
matogenesis, probably due to a disruption of glucose homeostasis. INSL6 is a major product of male germ cells, although it is
relatively unexplored with regard to its physiology or pharmacology, except that in mice disruption of the INSL6 gene leads to a
disruption of spermatogenesis. Clinically, relaxin analogues may be useful in the control of prostate cancer, and both relaxin and
INSL3 have been considered as sperm adjuvants for in vitro fertilization.
Abbreviations
GEO, gene expression omnibus; INSL3–6, insulin-like peptide 3–6; LGR7, leucine-rich repeat-containing GPCR 7, syn-
onymous with RXFP1; LH, luteinizing hormone; RLN2, H2-relaxin; RLN3, relaxin-3; RXFP1–4, relaxin family peptide
receptor 1–4
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Introduction
The relaxin-like peptides represent a family of peptide
hormones, which appear to have evolved in both vertebrate
and invertebrate lineages, evidently taking advantage of the
rigid peptide scaffold involving multiple cysteine bridges
common also to insulin and the insulin-like growth factors
(Yegorov and Good, 2012; Yegorov et al., 2014). This
scaffold allows the manifestation of a small relatively rigid
three-dimensional surface whose speciﬁcity of interaction
is dictated by the charges and side-groups of component
amino acids. Largely based on insulin and early studies on
relaxin in the pig, it is assumed that the mature circulating
peptides exist mostly as the ca. 6 kDa A–B heterodimers,
which appear to exhibit all of the epitopes essential for
speciﬁc activation of their cognate receptors. These hetero-
dimers never appear to be further modiﬁed by glycosylation
or other post-translational changes, such that their infor-
mational content resides exclusively within the folded
primary amino acid sequence. However, it is important to
note that at least for relaxin and insulin-like peptide 3
(INSL3), it is likely that a large proportion of the secreted
bioactive hormone is in fact represented by the A–B–C
unprocessed pro-form (MW 12–18 kDa), which retains the
ﬂexible intermediate C (connecting) peptide, which at least
in its interaction with receptors does not appear to hinder
speciﬁcity or binding in any way (Zarreh-Hoshyari-Khah
et al., 1999, 2001; Luo et al., 2009; Minagawa et al., 2012).
Whether the C-peptide has any function in its own right
or contributes to the stability or half-life of the peptides is
not known. There is little or no information concerning
the other members of the relaxin family, except that for
relaxin-3 and INSL5 binding to their respective cognate
receptors, relaxin family peptide receptor 3 (RXFP3) and
RXFP4, it would appear that cleavage of the C-peptide to
reveal the C-terminus of the B-chain is necessary for full
bioactivity (Luo et al., 2010a,b). From a technical
perspective, immunoassays using antibodies raised against
the A–B heterodimer, such as for relaxin or INSL3, will usu-
ally recognize both the 6 kDa heterodimer as well as the
larger pro-form (e.g. Zarreh-Hoshyari-Khah et al., 1999; Ivell
R and Anand-Ivell R, unpublished observations). Western
blotting of tissue extracts on the other hand, where success-
ful, will usually visualize the large pro-form only, and only
in exceptional circumstances is the smaller heterodimer
evident (e.g. Klonisch et al., 2003).
Whilst the principal branches of the vertebrate relaxin-
like family have existed since early chordates, notably INSL3
and ovarian H2 relaxin have evolved substantially to accom-
modate the new functions acquired by mammals in the
context of viviparity. This has led to the coining of the term
‘neohormones’ for all such peptides that have acquired regu-
latory or modulatory roles speciﬁcally linked to mammalian
traits, such as internal fertilization, a scrotal testis, lactation
and maternal behaviour (Ivell and Bathgate, 2006; Anand-
Ivell et al., 2013a). Importantly, the H2 relaxin locus, which
also includes relaxin-1 (also known as H1 relaxin), INSL4
and INSL6, is closely linked to the DMRT1 gene, which is rec-
ognized as the ancient sex-determination system for all verte-
brates, suggesting an important role for these peptides in
reproductive function (Ivell and Grutzner, 2009).
It is a feature of mammalian reproduction that the new
adaptations to viviparity, such as maternal recognition of
pregnancy, mode of placentation and implantation and
uterine or vaginal ejaculation, are highly variable. Accord-
ingly, it is not therefore surprising that those neohormones
regulating such processes are also very variable in their
expression and mode of action between species. The relaxin
family of peptide hormones is no exception. For that reason,
in the present review, emphasis will be given primarily to the
situation in humans, and animal models referred to where
they support or diverge from the human pattern.
Relaxin-like peptides and their
receptors
Of the relaxin-like family of peptide hormones in humans,
relaxin-3 and INSL5 appear to be restricted in their expression
to the brain and gastrointestinal tract respectively. In a repro-
ductive context, the major players are H2 relaxin and INSL3.
The roles of relaxin-1, INSL4 and INSL6 are less clear. Unlike
relaxin-3 and INSL5, which appear to speciﬁcally address a
class of GPCR with short extracellular domains, RXFP3 and
RXFP4, respectively, H2 relaxin and INSL3 are ligands for a
quite different class of GPCR, RXFP1 and RXFP2 respectively
(Bathgate et al., 2006a). These latter receptors are both charac-
terized by very large extracellular domains, comprising a sin-
gle LDLa receptor type A module and 10 leucine-rich repeats
(Bathgate et al., 2006a) and, at least in transfected cell
systems, mostly act by signalling through Gs to activate
adenylyl cyclase, unlike RXFP3 and RXFP4, which primarily
Tables of Links
TARGETS
RXFP1 receptor RXFP3 receptor
RXFP2 receptor RXFP4 receptor
LIGANDS
H2 relaxin (RNL2) Relaxin-1
INSL3 Relaxin-3 (RNL3)
INSL5
These Tables list key protein targets and ligands in this article which are hyperlinked to corresponding entries in http://www.guidetopharmacology.org,
the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016), and are permanently archived in the Concise Guide
to PHARMACOLOGY 2015/16 (Alexander et al., 2015).
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activate the PI3-kinase pathway. These act predominantly
through Gi and inhibit cAMP generation. The structure and
activity of these receptors are discussed in greater detail
elsewhere (Halls et al., 2015).
In a physiological context, it is important to note that the
EC50 for pure recombinant H2 relaxin at human RXFP1 recep-
tors is ca. 0.7 nM and, at human RXFP2 receptors, ca. 50 nM;
human INSL3 is unable to bind to RXFP1 receptors at all, but
interacts with human RXFP2 receptors with an EC50 of ca.
0.6 nM (Halls et al., 2015). Relaxin 3 can also interact with
human RXFP1 receptors, with an EC50 of ca. 15 nM, but can-
not interact with human RXFP2 receptors (Bathgate et al.,
2006b). These data are important because, even at the
highest concentrations recorded, H2 relaxin in
peripheral blood in women during pregnancy does not
exceed ca. 200 pg·mL1 (equivalent to ca. 35 pM) (Sherwood,
1994). Similarly, INSL3 in blood in women also does not
exceed ca. 200 pg·mL1 (Anand-Ivell et al., 2013b), whilst in
men, it can reach ca. 5 ng·mL1 (equivalent to ca. 900 pM)
(Anand-Ivell et al., 2006b). Thus, in humans, H2 relaxin and
INSL3 acting as endocrine hormones must be absolutely
speciﬁc for RXFP1 and RXFP2 receptors respectively. This
may be different within source tissues where relaxin may be
co-located with RXFP1 and/or RXFP2 receptors. For example,
in human follicular ﬂuid relaxin has been estimated at
1.8 ng·mg1 protein (Bastu et al., 2015), which, by applying
a protein content of 56 mg·mL1 (Valckx et al., 2012),
amounts to approximately 17 nM. The concentration may
be higher in other locations. Thus, only in source tissues is
there a possibility for a low level activation of RXFP2 recep-
tors by H2 relaxin, although not at all for RXFP1 receptors
by INSL3. There is only a single reference to RLN3 levels in
human blood (Ghattas et al., 2013), although the source of
this RLN3 remains unknown. Moreover, the data provided
are evidently erroneous: they exceed the upper limit of detec-
tion of the assay, as indicated by its manufacturer, by 1000-
fold, and validation of assay cross-reactivity to related
peptides is not reported. Neither INSL4 nor INSL6 is able to
interact with either human RXFP1 or human RXFP2 receptors
(Bogatcheva et al., 2003), and to date, these peptides still do
not have identiﬁable receptors of their own.
Relaxin and RXFP1 receptors in themale
reproductive system
H2 relaxin mRNA has been detected in the human testis
(Figure 1) using multiple tissue microarrays, although there
has been no systematic study of this tissue to identify its pre-
cise cellular location. Immunohistochemistry has failed to
Figure 1
Microarray gene transcript proﬁles for multiple human tissues for the genes RLN2, INSL3 and INSL6, extracted from the National Centre for
Biotechnology Information GEO database. Prostate and testis tissues are highlighted in green and red boxes, respectively.
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ﬁnd speciﬁc staining within the human testis using an anti-
porcine relaxin antibody (Yki-Järvinen et al., 1983). In con-
trast, the human prostate gland appears to be a relatively
consistent source of H2 relaxin expression, as determined
by microarrays (Figure 2) as well as by RT-PCR (Ivell et al.,
1989) and at the immunohistochemical level in the secretory
epithelium (Yki-Järvinen et al., 1983, Feng et al., 2007). This is
reinforced by its identiﬁcation also in cultured prostatic cells
and in prostate carcinoma (Feng et al., 2007; Silvertown et al.,
2007; Domińska et al., 2016a). Other tissues of the human
male reproductive system have not been assessed. It seems
likely that the immunoreactive relaxin identiﬁed in human
seminal plasma (Winslow et al., 1992; Armbruster et al.,
2001), according to its structure and sequence, is H2 relaxin
(Winslow et al., 1992) and is of prostatic origin. Although
some older studies have reported very high levels of seminal
relaxin, this might be due to a cross-reactivity and non-
speciﬁcity of the antibodies used (reviewed in Ivell et al.,
2011). With relaxin present in ejaculated seminal plasma, it
is logical to assume that this might react with speciﬁc recep-
tors within the distal female tract. The RXFP1 receptor is
expressed throughout the female reproductive tract, includ-
ing the cervix and vagina, although there is some doubt as
to its cellular localization with, in addition to smooth muscle
cells, both epithelial and stromal cells being implicated (Yao
et al., 2009; Soh et al., 2012). Most such studies have been
carried out in rodents, where there is a strong cervical
response to relaxin; however, clinical trials have failed to
show a signiﬁcant effect of relaxin on cervical softening in
women at term of pregnancy, when the greatest response to
introduced relaxin might be expected (Weiss et al., 2016).
Relatively little is known about the expression of RXFP1
receptors in the humanmale tract. The application of various
speciﬁc anti-RXFP1 antibodies to human testis sections failed
to identify speciﬁc epitopes (RI, unpublished), and no quanti-
tatively signiﬁcant hybridization signals for RXFP1 mRNA
have been shown for the testis on human tissue microarrays,
although it can be detected in human testis by RT-PCR
(Silvertown et al., 2010). This is different for the human pros-
tate gland, where consistent RXFP1 (LGR7) mRNA expression
is evident in both normal and cancer tissues (Feng et al.,
2007). The RXFP1 receptor has also been identiﬁed on ejacu-
lated human spermatozoa (Gianesello et al., 2009; Ferlin
et al., 2012), and relaxin has been shown to affect in vitro
human sperm parameters by decreasing apoptosis and
increasing mitochondrial activity, hyperactivation, calcium
and cAMP levels, as well as the acrosome reaction (Ferlin
et al., 2012).
Several studies have looked at the role of relaxin and
RXFP1 receptors in human prostate cancer and its progres-
sion. In particular, whilst RXFP1 receptor levels do not appear
to differ between normal and cancerous tissue, relaxin pep-
tide is more highly expressed in the latter cells (Thompson
et al., 2006; Feng et al., 2007; Vinall et al., 2011), and an
increased expression of RLN2 was reported during neuroen-
docrine differentiation of prostate cells (Figueiredo et al.,
2005). It was also shown that the mutant P53 regulates
RLN2 expression through direct binding to its gene promoter
(Vinall et al., 2006). It appears that H2 relaxin can regulate the
expression of prostate-speciﬁc antigen through an androgen-
mediated pathway by activation of the PI3K/Akt/NFκB and
components of β-catenin/Wnt signalling (Liu et al., 2008;
Figure 2
INSL3 peptide in the circulation of boys during pubertal development (based on data published in Johansen et al. 2014).
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Thompson et al., 2010; Vinall et al., 2011). In cell culture,
relaxin acts on prostate cancer lines to increase proliferation,
migration and invasiveness, presumably by increasing the
turnover of extracellular matrix (Klonisch et al., 2007; Feng
et al., 2010; Vinall et al., 2011; Domińska et al., 2016b). More-
over, transgenic overexpression of relaxin causes an increased
tumour growth in transgenic adenocarcinoma of the mouse
prostate resulting in a shorter survival time of the mice (Feng
et al., 2007). Similarly, xenografts with cells overexpressing
RLN2 grow faster and are more vascularized (Silvertown
et al., 2006). Finally, suppression of RXFP1 with siRNA or
peptide antagonists decreases human cancer cell xenograft
growth in immunocompromised mice (Silvertown et al.,
2007; Feng et al., 2010; Feng and Agoulnik, 2011; Neschadim
et al., 2014).
Relaxin and RXFP1 receptors have been more intensively
studied in various animal models, including rats, mice and
pigs. Whilst similar in some ways to the human, each of these
species also exhibits signiﬁcant differences from the human
situation. The boar testis expresses substantial amounts of
relaxin exclusively from the interstitial Leydig cells,
conﬁrming an earlier immunohistochemical study (Dubois
and Dacheux, 1978), and it appears to act on RXFP1 receptors
located both on Leydig cells as well as on germ cells within
the seminiferous epithelium (Min and Sherwood, 1998; Kato
et al., 2010). Another immunohistochemical analysis using
the pig, however, failed to identify any speciﬁc relaxin signal
not only in testis but also in the prostate, epididymis or
bulbo-urethral gland (Kohsaka et al., 1992). This study only
showed relaxin immunoreactivity in the seminal vesicles. In
mice, microarray hybridization [gene expression omnibus
(GEO) database] generally fails to indicate relaxin mRNA
signals in the testes, although speciﬁc RT-PCR does identify
relaxin mRNA both here and in the epididymis, but not in
any other tissues of the male tract (RI, unpublished observa-
tions). RXFP1 mRNA was identiﬁed by RT-PCR in diverse
somatic cells of the mouse testis (Ivell et al., 2011). An earlier
study revealed the expression of both relaxin and RXFP1
receptors in the mouse testis (Samuel et al., 2003). The rat
testis also expresses relaxin mRNA but apparently in the
Sertoli cells (Cardoso et al., 2010), rather than in the intersti-
tial compartment. Also, the prostate gland of this species
appears to express relaxin mRNA (Cardoso et al., 2010).
RXFP1 receptor mRNA has also been identiﬁed in rat Sertoli
cells as well as in the prostate gland and in the vas deferens
(Cardoso et al., 2010), supporting functional studies suggest-
ing that relaxin affects Sertoli cell signalling and the vas
deferens (Cardoso et al., 2010; Nascimento et al., 2012).
Knockout mice have been generated with deletions in
both the relaxin gene as well as in the gene for RXFP1 recep-
tors (Zhao et al., 1999; Kamat et al., 2004; Kaftanovskaya
et al., 2015a). The resulting phenotype in the male and its in-
terpretation is somewhat controversial. Whereas the initial
descriptions indicated a modest disruption of spermatogene-
sis in early generations, it appears that this phenotype is
largely lost in later generations. In agreement with studies
on different organ systems (Bennett, 2009), the loss of relaxin
production appeared to induce a local ﬁbrosis in both the
testes and prostate gland (Samuel et al., 2003). This, however,
was not evident in studies carried out on similar animals
several years later (Ganesan et al., 2009; Ivell et al., 2011).
In conclusion, there appear to be substantial differences
between species in the relative levels of expression, particu-
larly of relaxin, in different organs of the male reproductive
system, and caution is therefore warranted in translating
ﬁndings from animal models to humans.
INSL3 in the male reproductive system
INSL3, because of its similarity to relaxin, was originally
referred to as the relaxin-like factor. It was independently
identiﬁed, using differential cloning techniques, as a highly
expressed transcript in the testes of boars (Adham et al.,
1993) and mice (Pusch et al., 1996). Subsequently, it was also
shown to be expressed at high levels in the human testis (Ivell
et al., 1997). In all mammalian species so far examined, INSL3
is a major secretory product of mature interstitial Leydig cells.
Moreover, INSL3 in the circulation derives exclusively from
the Leydig cells and from nowhere else, making INSL3 a
unique biomarker for the functional capacity of the Leydig
cell (Ivell et al., 2013). In normal men, the circulating INSL3
concentration is approximately 1 ng·mL1 (range 0.5–2.0-
ng·mL1), whereas in Klinefelter patients, those with severe
infertility, in uniorchid men or in those with a suppressed
hypothalamo-pituitary-gonadal (HPG) axis, the INSL3 con-
centration is signiﬁcantly less or undetectable (Foresta et al.,
2004; Bay et al., 2005). Importantly, it is expressed constitu-
tively and is acutely independent of the HPG axis. What this
means is that while the other major Leydig cell product, tes-
tosterone, can be acutely (within minutes) up-regulated by
pituitary luteinizing hormone (LH), INSL3 is not affected.
Nevertheless, since INSL3 is a product of more differentiated
Leydig cells, factors like LH, which may chronically (days)
affect the differentiation status of Leydig cells, can in the long
term alter INSL3 expression (Ivell et al., 2014). This helps to
explain, for example, why hCG treatment over several weeks
in men with hypothalamic hypogonadism can improve
circulating INSL3 (Foresta et al., 2004); whereas uniorchid
subjects similarly treated but for only 3–4 days showed no
such increase in INSL3 (Bay et al., 2005). In the human male,
circulating INSL3 is at the limit of detection before puberty
and increases concomitantly with the differentiation of the
Leydig cells (Ferlin et al., 2006b; Wikström et al., 2006;
Johansen et al., 2014; Figure 2). As shown by the longitudinal
data in Figure 2 and illustrated in other studies (Ferlin et al.,
2006a,b; Wikström et al., 2006), there is substantial variation
in INSL3 levels during puberty, the origin of which is still
largely unknown. In adult men, peripheral INSL3 concentra-
tion is generally in the range 0.5–2.0 ng·mL1, declining
steadily with age (ca. 12% per decade) (Anand-Ivell et al.,
2006a). Because there appears to be no compensatory feed-
back via the HPG axis, as for gonadal steroids, this age-
dependent decline is greater than that for testosterone, which
only declines at ca. 6% per decade, because of the steady
increase in LH secretion with age (Anand-Ivell et al., 2006b).
Importantly, INSL3 appears to be highly consistent as a clini-
cal parameter within an individual over periods of several
years and is not subject to short-term variations like testoster-
one (Anand-Ivell, unpublished observations). Because INSL3
is only dependent on Leydig cell numbers (which do not sig-
niﬁcantly change with age within an individual) and their
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differentiation status – together referred to as Leydig cell
functional capacity – in men who have had one testis
removed because of seminoma, circulating INSL3 levels are
signiﬁcantly and permanently reduced, unlike testosterone,
which, through a compensatory increased LH, is restored to
normal intact values in these men (Anand-Ivell et al.,
2006b). Although, it should be noted that over time,
uniorchid men do show some increase in INSL3 levels above
the expected 50% of the intact level, due to the chronically
increased LH secretion and consequently increased differen-
tiation status of the uniorchid Leydig cells.
INSL3 acts uniquely at the RXFP2 receptor and, in adult
men, appears to have two functions. As an endocrine
hormone, INSL3 probably modulates bonemetabolism, since
individuals with a dysfunctionally mutated RXFP2 receptor
exhibit signiﬁcant osteopaenia and osteoporosis (Ferlin
et al., 2008a). INSL3 also appears to act locally within the tes-
tis on germ cells. Within the human testis, the RXFP2
receptor is expressed both on Leydig cells themselves as well
as on predominantly post-meiotic germ cells, as demon-
strated by speciﬁc immunohistochemistry (Anand-Ivell
et al., 2006a). In a study looking at a steroidal male contracep-
tion regimen, it was shown that men with greater circulating
INSL3 levels showed higher residual spermatogenesis (Amory
et al., 2007), suggesting that INSL3 was acting as an anti-
apoptotic survival agent vis-à-vis germ cells.
All malemammals so far investigated show substantial ex-
pression of INSL3 in the interstitial Leydig cells of the testis
and nowhere else. As in humans, studies in boars, bulls, deer,
dogs, cats and rodents (Bathgate et al., 1996; Pusch et al., 1996;
Spiess et al., 1999; Hombach-Klonisch et al., 2004; Pathirana
et al., 2011; Minagawa et al., 2012; Braun et al., 2015) all show
negligible prepubertal expression of INSL3, which increases
with pubertal development to reach a maximum in early
adulthood. Studies in rats and boars using either a speciﬁc
RXFP2 antagonist or a passive immunization protocol, re-
spectively, both conﬁrm the importance of INSL3 as a germ
cell survival factor (Del Borgo et al., 2006; Sagata et al.,
2015). Studies in mice in which the RXFP2 gene has been de-
leted also show signiﬁcant osteopenia, supporting a role for it
in bonemetabolism (Ferlin et al., 2008a,b). However, it should
be noted that in adult mice in which the RXFP2 gene has been
selectively deleted in germ cells, there is no evidence for an ef-
fect of INSL3 on germ cell survival (Huang et al., 2012). In or-
der for INSL3 to act on the germ cell receptors, the peptide
hormone needs to cross the blood-testis-barrier comprising
Sertoli cell tight junctions from the interstitial compartment
into the seminiferous tubule lumen. Careful measurements
of INSL3 peptide within different testicular compartments
in both rats and boars indicate indeed that this occurs, pre-
sumably by some speciﬁc transport mechanism (Anand-Ivell
et al., 2009). Taken together, and unlike the situation for re-
laxin in the male tract, there appears to be muchmore consis-
tency between species in the expression and physiology of
INSL3 and its receptor, RXFP2, in the adult male mammal.
INSL3 in the fetus
INSL3 is also expressed by the Leydig cells of the testes in the
male fetus. These Leydig cells represent a separate population
from the adult-type Leydig cells, which differentiate after
puberty. Whereas it appears that in rodents, fetal and adult
Leydig cells represent discrete cell populations
(Kaftanovskaya et al., 2015b), for other species, this is less
clear. It seems possible for a human that there is a perinatal
involution of the fetal population, which then
redifferentiates in late infancy (Teerds and Huhtaniemi,
2015). Fetal Leydig cells begin to differentiate from undiffer-
entiated mesenchyme cells immediately following
SRY-driven sex determination in order to provide androgens,
which are needed to promote gender-speciﬁc differentiation
of tissues and behaviour. The major phenotype of mice, in
which either INSL3 or the RXFP2 receptor have been deleted,
is the failure of the ﬁrst phase of testicular descent within the
abdomen (Nef and Parada, 1999; Zimmermann et al., 1999;
Overbeek et al., 2001; Gorlov et al., 2002). This occurs at
different times during gestation in different mammalian
species (Figure 3), but occurs shortly after testis formation
and is concomitant with the differentiation of the Leydig
cells. From studies in rodents, we know that INSL3 is essential
for this process by acting on RXFP2 receptors expressed
within the gubernacular ligaments, causing these to expand
and anchor the testes in the inguinal region, while the other
organs including the kidneys grow away in an antero-dorsal
direction. In a second inguino-scrotal phase, androgens
under the inﬂuence of the developing HPG axis then
promote the movement of the testes through the inguinal
ring into the scrotum (Kaftanovskaya et al., 2012). Studies
measuring INSL3 in human amniotic ﬂuid collected at rou-
tine amniocentesis (Anand-Ivell et al., 2008; Jensen et al.,
2015), or looking at INSL3 in amniotic or allantoic ﬂuids as
well as fetal serum from pigs (Vernunft et al., 2016), cows
(Anand-Ivell et al., 2011) and rats (Anand-Ivell and Ivell,
2014), all conﬁrm the high expression of INSL3 at precisely
that time accompanying the ﬁrst tranbsabdominal phase of
testicular descent. Because INSL3 is only expressed by the
male fetus, it also acts as a useful biomarker speciﬁc for fetal
gender and has been used to show transfer of the fetal
hormone in calves across the placenta to the maternal circu-
lation (Anand-Ivell et al., 2011) or in pigs between male and
female fetuses (Vernunft et al., 2016).
Several studies have attempted to link fetal INSL3 expres-
sion with the common congenital condition of cryptorchi-
dism, whereby one or both testes fail to descend into the
scrotum. Firstly, it is important to understand that cryptor-
chidism is a very complex and multifactorial condition
(Hutson et al., 2010); secondly, a recent meta-analysis of rat
studies showed that fetal INSL3 mRNA expression probably
needs to be reduced by at least 40% before there is any impact
on phenotype (Gray et al., 2016). Some studies in human
babies have used cord blood, where it is evident that the
INSL3measured can only be a residual of whatmay have been
present during the ﬁrst transabdominal phase of testis
descent in the transition between ﬁrst and second trimester,
some 4–6 months earlier (Bay et al., 2007; Chevalier et al.,
2015; Fenichel et al., 2015). Cord blood INSL3 concentration
is usually around 50–100 pg·mL1, compared with a probable
blood concentration (based on extrapolations from other
species and from human amniotic ﬂuid collected in the early
second trimester) closer to 1 ng·mL1. Nevertheless, such
studies do suggest that INSL3 concentration may have been
BJP R Ivell et al.
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signiﬁcantly reduced in cases of cryptorchidism. However, a
recent very large case–control study of human amniotic ﬂuid
samples collected throughout the second trimester did not
show evidence of any reduction of INSL3 in cryptorchids
compared with controls (Jensen et al., 2015).
Studies have been performed to determine whether there
is an association between cryptorchidism in human patients
with the presence of mutant INSL3 and RXFP2 alleles
(Bogatcheva and Agoulnik, 2005). The frequency of such
mutations is usually low (<1–3%) and accounts for only a
small portion of all cryptorchidism cases. This is not
unexpected as any mutation affecting fertility will be under
strong negative selection in the population. Infertility in car-
rier fathers caused by undescended testis will prevent trans-
mission of the mutant allele to the next generation. Thus,
the population spread of the male-limited mutation can be
achieved either through female transmission or through an
accumulation in the population of genetic modiﬁers
suppressing the harmful phenotype. Both of these mecha-
nisms have been found in the case of the T222P variant allele
of the RXFP2 receptor (Gorlov et al., 2002). Functional assays
have demonstrated that the mutant T222P receptor failed to
be expressed on the cell surface membrane (Bogatcheva
et al., 2007). While in the Italian population, heterozygosity
for T222P was strongly linked to cryptorchidism, and in all
the cases analysed there was a maternal transmission of this
allele; in Spain and Northern Africa, T222P heterozygotes
were equally present in patient and control groups (El Houate
et al., 2008; Ferlin et al., 2008a,b; Feng et al., 2009; Ars et al.,
2010). Similarly, while some mutations in INSL3 resulted in
its functional deﬁciency and or were exclusively present in
cryptorchid patients (Tomboc et al., 2000; Bogatcheva et al.,
2003; Ferlin et al., 2006a; El Houate et al., 2007), other
mutant alleles were also detected in the control population
(Koskimies et al., 2000; Yamazawa et al., 2007; Mamoulakis
et al., 2014; Huang et al., 2016).
Similar to INSL3 in the adult male, there also do not
appear to be major differences in fetal INSL3 between mam-
malian species, except in timing of expression to coincide
with the main period of transabdominal testicular descent,
and in the hormonal control of Leydig cell differentiation,
which appears to differ particularly between rodents and
other species (Teerds and Huhtaniemi, 2015). Because of its
highly speciﬁc expression by Leydig cells only in the male
fetus, INSL3 is proving to be a powerful sentinel biomarker
for the effects of gestational exposure to environmental
endocrine disruptors (Anand-Ivell and Ivell, 2014). These
are substances often with steroid-like properties, which are
widespread in the environment and have been shown to alter
endocrine parameters during fetal life with consequences for
adult physiology and possibly subsequent generations
(Bergman et al., 2013). In this context, it appears that not all
species are similar, with rodent Leydig cells seeming to be
more susceptible to exposure to certain such xenobiotics
than, for example, human cells (Habert et al., 2014).
Other relaxin-like peptides in male
reproduction
INSL6 is highly expressed in post-meiotic germ cells within
the testes (Figure 1) and possibly at lower levels in other tis-
sues, such as skeletal muscle, and at least in vitro has been
shown to be a secretory peptide, presumably contributing to
the seminal ﬂuid leaving the testis. Originally identiﬁed as
an expressed sequence tag from the human testis (Lok et al.,
2000), it has since also been identiﬁed as a germ-cell-speciﬁc
transcript in rodents (Lok et al., 2000; Burnicka-Turek et al.,
2009), as well as being present in the genomes of all
sequencedmammals. Mice in which the INSL6 gene has been
deleted show a marked disruption of spermatogenesis with
meiotic arrest (Burnicka-Turek et al., 2009), suggesting an
Figure 3
Testis development and testicular descent in various mammal species. Gestation is expressed as a percentage with conception at 0% and term of
pregnancy at 100%. F, testis formation; TA, transabdominal phase of testis descent; IS, inguino-scrotal phase of testis descent. The red ovals in-
dicate the periods of maximum INSL3 expression and correspond approximately to the ‘male programming window’ for each species (modiﬁed
after Anand-Ivell and Ivell, 2014).
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important role in sperm formation. In support of this idea, a
single missense mutation in the human INSL6 gene was
recently identiﬁed in an infertile male patient, though no
causative studies were undertaken (Chen et al., 2011). To
date, however, no speciﬁc receptor for human INSL6 has been
discovered, and it appears incapable of interacting with any
of the known relaxin and insulin-family peptide receptors.
RLN3 is best known as a brain neuropeptide (Bathgate
et al., 2013) but has also been identiﬁed at very low transcript
levels within the interstitial cells of testes from monkeys
(Silvertown et al., 2010) and mice (Ivell et al., 2011). Also,
transcripts for its cognate receptors RXFP3 and RXFP4 have
been identiﬁed within the testes (Silvertown et al., 2010; Ivell
et al., 2011). In contrast, the closely related gut peptide INSL5
is not signiﬁcantly detectable in any part of the male tract
(GEO database). However, whereas the phenotype of RLN3
knockout mice does not suggest any essential male reproduc-
tive function (Smith et al., 2009), that for INSL5 indicates a
mildly reduced fertility in both males and females possibly
due to an impact on glucose metabolism (Burnicka-Turek
et al., 2012). INSL4 is only known to be expressed in the
human placenta, and is not detectable in any tissue of the
male reproductive tract (GEO database).
Clinical applications of relaxin-like
peptides
To date, only H2 relaxin has been trialled in a clinical/
therapeutic context and then for indications generally unre-
lated to male reproduction (Tietjens and Teerlink, 2016).
Importantly, H2 relaxin has passed essential safety criteria
for use in humans. However, a potential use of relaxin inmale
fertility treatment was analysed with regard to sperm survival
and fertilization, through its effects on motility, capacitation
and the acrosome reaction (Agoulnik, 2007; Ferlin et al.,
2012). This would be beneﬁcial in an in vitro fertilization set-
ting, especially when dealing with frozen or functionally de-
ﬁcient sperm, or when there is a limited number of sperm
from the infertile patients (Lessing et al., 1986). Similarly,
the application of relaxin might have even larger use in com-
mercial farm animal breeding where assisted reproduction
procedures are widely used. Again, the sperm-activating
properties of relaxin would be beneﬁcial especially in situa-
tions of reduced sperm motility or unanticipated delayed
insemination, using either fresh or frozen–thawed semen
(Feugang et al., 2015). However, the somewhat modest and
variable effects of relaxin on sperm coupled with the high
cost of the recombinant peptide can be limiting factors in
these applications.
As with other peptide-based drugs, there are well-
recognized challenges in using relaxin as a therapeutic agent
especially in a chronic setting. The half-life of the unmodiﬁed
relaxin peptide is short (Yoshida et al., 2012) and thus has to
be administered i.v. The cost of production for recombinant
peptide is signiﬁcant. An additional and still understudied
issue is the potential immune response to injections. The
use of recently discovered small molecule agonists of RXFP1
receptors might overcome these problems (Xiao et al.,
2013). Such small compounds are easy to synthesize; they
are stable in vivo, and they can be delivered through different
routes, including oral or ectopic application. It was shown,
however, that the compounds activate the relaxin receptor
through allosteric mechanisms, suggesting that downstream
cellular signalling might be biased (Huang et al., 2015; Hu
et al., 2016). Further investigation of the utility of these ago-
nists, especially in animal models, is warranted.
Concluding remarks
Theoretically, the relaxin family of peptide hormones and
their cognate receptors lend themselves ideally for use as
therapeutic or pharmacological targets. As neohormones,
they subserve a set of properties, particularly related to mam-
malian reproduction and ageing, which are modulatory
rather than being ancient and essential. This is reﬂected in
the safety record for relaxin, which indicates few if any nega-
tive side-effects. However, we still understand very little
about the physiology of these peptides, especially with
respect to human, as opposed to animal models. Being evolu-
tionarily modern hormones, as discussed, there is likely to be
considerable between-species variation in their physiology,
which still needs to be properly addressed. For relaxin-like
peptides, male reproduction is relatively unexplored, and
we can expect some exciting ﬁndings in the next few years.
Author contributions
All authors have contributed equally to the conception and
writing of this review. R.I. had overall management.
Conﬂict of interest
The authors declare no conﬂicts of interest.
References
Adham IM, Burkhardt E, Benahmed M, Engel W (1993). Cloning of a
cDNA for a novel insulin-like peptide of the testicular Leydig cells. J
Biol Chem 268: 26668–26672.
Agoulnik AI (2007). Relaxin and related peptides in male
reproduction. Adv Exp Med Biol 612: 49–64.
Alexander SPH, Davenport AP, Kelly E, Marrion N, Peters JA,
Benson HE et al. (2015). The concise guide to PHARMACOLOGY
2014/16: G protein-coupled receptors. Br J Pharmacol 172:
5744–5869.
Amory JK, Page ST, Anawalt BD, Coviello AD, Matsumoto AM,
Bremner WJ (2007). Elevated end-of-treatment serum INSL3 is
associated with failure to completely suppress spermatogenesis in
men receiving male hormonal contraception. J Androl 28: 548–554.
Anand-Ivell R, Dai Y, Ivell R (2013a). Neohormones as biomarkers of
reproductive health. Fertil Steril 99: 1153–1160.
Anand-Ivell R, Heng K, Hafen B, Setchell B, Ivell R (2009). Dynamics
of INSL3 peptide expression in the rodent testis. Biol Reprod 81:
480–487.
BJP R Ivell et al.
8 British Journal of Pharmacology (2017) •• ••–••
Anand-Ivell R, Hiendleder S, Viñoles C, Martin GB, Fitzsimmons C,
Eurich A et al. (2011). INSL3 in the ruminant: a powerful indicator of
gender- and genetic-speciﬁc feto-maternal dialogue. PLoS One 6:
e19821.
Anand-Ivell R, Ivell R, Driscoll DA, Manson J (2008). INSL3 Levels in
amniotic ﬂuid from human male fetuses. Hum Reprod 23:
1180–1186.
Anand-Ivell R, Ivell R (2014). INSL3 as a monitor of endocrine
disruption. Reproduction 147: R87–R95.
Anand-Ivell R, Tremellen K, Dai Y, Heng K, Yoshida M, Knight PG
et al. (2013b). Circulating insulin-like factor 3 (INSL3) in healthy and
infertile women. Hum Reprod 28: 3093–3102.
Anand-Ivell RJK, Relan V, Balvers M, Fritsch M, Bathgate RAD, Ivell R
(2006a). Expression of the insulin-like peptide 3 (INSL3) hormone-
receptor (LGR8) system in the testis. Biol Reprod 74: 945–953.
Anand-Ivell RJK, Wohlgemuth J, Haren MT, Hope PJ, Hatzinikolas G,
Wittert G et al. (2006b). Peripheral INSL3 concentrations decline with
age in a large population of Australian men. Int J Androl 29: 618–626.
Armbruster FP, Grön HJ, Maier I, Becker S, Bailer SM, Lippert TH et al.
(2001). A sensitive homologous radioimmunoassay for human
relaxin-2 (h-RLX-2) based on antibodies characterized by epitope
mapping studies. Eur J Med Res 6: 1–9.
Ars E, Lo Giacco D, Bassas L, Nuti F, Rajmil O, Ruiz P et al. (2010).
Further insights into the role of T222P variant of RXFP2 in non-
syndromic cryptorchidism in two Mediterranean populations. Int J
Androl 34: 333–338.
Bastu E, Gokulu SG, Dural O, Yasa C, Bulgurcuoglu S,
Karamustafaoglu Balci B et al. (2015). The association between
follicular ﬂuid levels of cathepsin B, relaxin or AMH with clinical
pregnancy rates in infertile patients. Eur J Obstet Gynecol Reprod Biol
187: 30–34.
Bathgate R, Balvers M, Hunt N, Ivell R (1996). The relaxin like factor
(RLF) is upregulated in the bovine ovary of the cycle and pregnancy:
sequence and mRNA analysis. Biol Reprod 55: 1452–1457.
Bathgate RA, Halls ML, van der Westhuizen ET, Callander GE, Kocan
M, Summers RJ (2013). Relaxin family peptides and their receptors.
Physiol Rev 93: 405–480.
Bathgate RA, Hsueh AJ, Ivell R, Sanborn BM, Sherwood OD, Summers
RJ (2006a). International union of pharmacology. Recommendations
for the nomenclature of receptors for relaxin family peptides.
Pharmacol Rev 58: 7–31.
Bathgate RA, Lin F, Hanson NF, Otvos L Jr, Guidolin A, Giannakis C
et al. (2006b). Relaxin-3: improved synthesis strategy and
demonstration of its high-afﬁnity interaction with the relaxin
receptor LGR7 both in vitro and in vivo. Biochemistry 45:
1043–1053.
Bay K, Hartung S, Ivell R, Schumacher M, Jurgensen D, Jorgensen N
et al. (2005). Insulin-like factor 3 serum levels in 135 normal men and
85 men with testicular disorders: relationship to the luteinizing
hormone-testosterone axis. J Clin Endocrinol Metab 90: 3410–3418.
Bay K, Virtanen HE, Hartung S, Ivell R, Main KM, Skakkebaek NE et al.
(2007). Insulin-like factor 3 levels in cord blood and serum from
children: effects of age, postnatal hypothalamic–pituitary-gonadal
axis activation, and cryptorchidism. J Clin Endocrinol Metab 92:
4020–4027.
Bennett RG (2009). Relaxin and its role in the development and
treatment of ﬁbrosis. Transl Res 154: 1–6.
Bergman A, Heindel JJ, Kasten T, Kidd KA, Jobling S, Neira M et al.
(2013). The impact of endocrine disruption: a consensus statement
on the state of the science. Environ Health Perspect 121: A101–A106.
Bogatcheva NV, Agoulnik AI (2005). INSL3/LGR8 role in testicular
descent and cryptorchidism. Reprod Biomed Online 10: 49–54.
Bogatcheva NV, Ferlin A, Feng S, Truong A, Gianesello L, Foresta C
et al. (2007). T222P mutation of the insulin-like 3 hormone receptor
LGR8 is associated with testicular maldescent and hinders receptor
expression on the cell surface membrane. Am J Physiol Endocrinol
Metab 292: E138–E144.
Bogatcheva NV, Truong A, Feng S, Engel W, Adham IM, Agoulnik AI
(2003). GREAT/LGR8 is the only receptor for insulin-like 3 peptide.
Mol Endocrinol 17: 2639–2646.
Braun BC,Muller K, Jewgenow K (2015). Expression proﬁles of relaxin
family peptides and their receptors indicate inﬂuence on
spermatogenesis in the domestic cat (Felis catus). Domest Anim
Endocrinol 52: 25–34.
Burnicka-Turek O, Mohamed BA, Shirneshan K, Thanasupawat T,
Hombach-Klonisch S, Klonisch T et al. (2012). INSL5-deﬁcient mice
display an alteration in glucose homeostasis and an impaired fertility.
Endocrinology 153: 4655–4665.
Burnicka-Turek O, Shirneshan K, Paprotta I, Grzmil P, Meinhardt A,
Engel W et al. (2009). Inactivation of insulin-like factor 6 disrupts the
progression of spermatogenesis at late meiotic prophase.
Endocrinology 150: 4348–4357.
Cardoso LC, Nascimento AR, Royer C, Porto CS, Lazari MF (2010).
Locally produced relaxin may affect testis and vas deferens function
in rats. Reproduction 139: 185–196.
Chen GW, Luo X, Liu YL, Jiang Q, Qian XM, Guo ZY (2011). R171H
missense mutation of INSL6 in a patient with spermatogenic failure.
Eur J Med Genet 54: e455–e457.
Chevalier N, Brucker-Davis F, Lahlou N, Coquillard P, Pugeat M,
Pacini P et al. (2015). A negative correlation between insulin-like
peptide 3 and bisphenol A in human cord blood suggests an effect of
endocrine disruptors on testicular descent during fetal development.
Hum Reprod 30: 447–453.
Del Borgo MP, Hughes RA, Bathgate RA, Lin F, Kawamura K, Wade JD
(2006). Analogs of insulin-like peptide 3 (INSL3) B-chain are LGR8
antagonists on vitro and in vivo. J Biol Chem 281: 13068–13074.
Domińska K, Ochędalski T, Kowalska K, Matysiak-Burzyńska ZE,
Płuciennik E, Piastowska-Ciesielska AW (2016a). A common effect of
angiotensin II and relaxin 2 on the PNT1A normal prostate epithelial
cell line. J Physiol Biochem 72: 381–392.
Domińska K, Ochędalski T, Kowalska K, Matysiak-Burzyńska ZE,
Płuciennik E, Piastowska-Ciesielska AW (2016b). Interaction between
angiotensin II and relaxin 2 in the progress of growth and spread of
prostate cancer cells. Int J Oncol 48: 2619–2628.
Dubois MP, Dacheux JL (1978). Relaxin, a male hormone?
Immunocytological localization of a related antigen in the boar testis.
Cell Tissue Res 187: 201–214.
El Houate B, Rouba H, Imken L, Sibai H, Chaﬁk A, Boulouiz R et al.
(2008). No association between T222P/LGR8 mutation and
cryptorchidism in the Moroccan population. Horm Res 70: 236–239.
El Houate B, Rouba H, Sibai H, Barakat A, Chaﬁk A, Chadli el B et al.
(2007). Novel mutations involving the INSL3 gene associated with
cryptorchidism. J Urol 177: 1947–1951.
Feng S, Agoulnik AI (2011). Expression of LDL-A module of relaxin
receptor in prostate cancer cells inhibits tumorigenesis. Int J Oncol
39: 1559–1565.
Relaxin-like peptides in male reproduction BJP
British Journal of Pharmacology (2017) •• ••–•• 9
Feng S, Agoulnik IU, Bogatcheva NV, Kamat AA, Kwabi-Addo B, Li R
et al. (2007). Relaxin promotes prostate cancer progression. Clin
Cancer Res 13: 1695–1702.
Feng S, Agoulnik IU, Truong A, Li Z, Creighton CJ, Kaftanovskaya EM
et al. (2010). Suppression of relaxin receptor RXFP1 decreases prostate
cancer growth and metastasis. Endocr Relat Cancer 17: 1021–1033.
Feng S, Ferlin A, Truong A, Bathgate R, Wade JD, Corbett S et al.
(2009). INSL3/RXFP2 signaling in testicular descent. Ann N Y Acad
Sci 1160: 197–204.
Fenichel P, Lahlou N, Coquillard P, Panaia-Ferrari P, Wagner-Mahler
K, Brucker-Davis F (2015). Cord blood insulin-like peptide 3 (INSL3)
but not testosterone is reduced in idiopathic cryptorchidism. Clin
Endocrinol (Oxf) 82: 242–247.
Ferlin A, Bogatcheva NV, Gianesello L, Pepe A, Vinanzi C, Agoulnik
AI et al. (2006a). Insulin-like factor 3 gene mutations in testicular
dysgenesis syndrome: clinical and functional characterization. Mol
Hum Reprod 12: 401–406.
Ferlin A, Garolla A, Rigon F, Rasi Caldogno L, Lenzi A, Foresta C
(2006b). Changes in serum insulin-like factor 3 during normal male
puberty. J Clin Endocrinol Metab 91: 3426–3431.
Ferlin A, Menegazzo M, Gianesello L, Selice R, Foresta C (2012). Effect
of relaxin on human sperm functions. J Androl 33: 474–482.
Ferlin A, Pepe A, Gianesello L, Garolla A, Feng S, Giannini S et al.
(2008a). Mutations in the insulin-like factor 3 receptor are associated
with osteoporosis. J Bone Miner Res 23: 683–693.
Ferlin A, Zuccarello D, Zuccarello B, Chirico MR, Zanon GF, Foresta C
(2008b). Genetic alterations associated with cryptorchidism. JAMA
300: 2271–2276.
Feugang JM, Rodriguez-Munoz JC, Dillard DS, CrenshawMA,Willard
ST, Ryan PL (2015). Beneﬁcial effects of relaxin on motility
characteristics of stored boar spermatozoa. Reprod Biol Endocrinol
13: 24.
Figueiredo KA, Palmer JB, Mui AL, Nelson CC, Cox ME (2005).
Demonstration of upregulated H2 relaxin mRNA expression during
neuroendocrine differentiation of LNCaP prostate cancer cells and
production of biologically active mammalian recombinant 6
histidine-tagged H2 relaxin. Ann N Y Acad Sci 1041: 320–327.
Foresta C, Bettella A, Vinanzi C, Dabrilli P, Meriggioloa MC, Garolla A
et al. (2004). A novel circulating hormone of testis origin in humans. J
Clin Endocrinol Metab 89: 5952–5958.
Ganesan A, Klonisch T, McGuane JT, Feng S, Agoulnik AI, Parry LJ
(2009). Normal prostate morphology in relaxin-mutant mice. Reprod
Fertil Dev 21: 440–450.
Ghattas MH, Mehanna ET, Mesbah NM, Abo-Elmatty DM (2013).
Relaxin-3 is associated with metabolic syndrome and its component
traits in women. Clin Biochem 46: 45–48.
Gianesello L, Ferlin A, Menegazzo M, Pepe A, Foresta C (2009). RXFP1
is expressed on the sperm acrosome, and relaxin stimulates the
acrosomal reaction of human spermatozoa. Ann N Y Acad Sci 1160:
192–193.
Gorlov IP, Kamat A, Bogatcheva NV, Jones E, Lamb DJ, Truong A et al.
(2002). Mutations of the GREAT gene cause cryptorchidism. Hum
Mol Genet 11: 2309–2318.
Gray LE Jr, Furr J, Tatum-Gibbs KR, Lambright C, Sampson H, Hannas
BR et al. (2016). Establishing the ‘biological relevance’ of dipentyl
phthalate reductions in fetal rat testosterone production and plasma
and testis testosterone levels. Toxicol Sci 149: 178–191.
Habert R, Muczynski V, Grisin T, Moison D, Messiaen S, Frydman R
et al. (2014). Concerns about the widespread use of rodent models for
human risk assessments of endocrine disruptors. Reproduction 147:
R119–R129.
Halls ML, Bathgate RA, Sutton SW, Dschietzig TB, Summers RJ (2015).
International union of basic and clinical pharmacology. XCV. Recent
advances in the understanding of the pharmacology and biological
roles of relaxin family peptide receptors 1–4, the receptors for relaxin
family peptides. Pharmacol Rev 67: 389–440.
Hombach-Klonisch S, Schon J, Kehlen A, Blottner S, Klonisch T
(2004). Seasonal expression of INSL3 and Lgr8/Insl3 receptor
transcripts indicates variable differentiation of Leydig cells in the roe
deer testis. Biol Reprod 71: 1079–1087.
Hu X, Myhr C, Huang Z, Xiao J, Barnaeva E, Ho BA et al. (2016).
Structural insights into the activation of human relaxin family
peptide receptor 1 by small molecule agonists. Biochemistry 55:
1772–1783.
Huang X, Jia J, SunM, Li M, Liu N (2016). Mutational screening of the
INSL3 gene in azoospermic males with a history of cryptorchidism.
Andrologia 48: 835–839.
Huang Z, Myhr C, Bathgate RA, Ho BA, Bueno A, Hu X et al. (2015).
Activation of relaxin family receptor 1 from different mammalian
species by relaxin peptide and small-molecule agonist ML290. Front
Endocrinol 6: 128.
Huang Z, Rivas B, Agoulnik AI (2012). Insulin-like 3 signaling is
important for testicular descent but dispensable for spermatogenesis
and germ cell survival in adult mice. Biol Reprod 87: 143.
Hutson JM, Balic A, Nation T, Southwell B (2010). Cryptorchidism.
Semin Pediatr Surg 19: 215–224.
Ivell R, Balvers M, Domagalski R, Ungefroren H, Hunt N, Schulze W
(1997). The relaxin-like factor: a highly speciﬁc and constitutive new
marker for Leydig cells in the human testis. Mol Hum Reprod 3:
101–108.
Ivell R, Bathgate RAD (2006). Hypothesis: neohormone systems as
exciting targets for drug development. Trends Endocrinol Metab 17:
123.
Ivell R, Grutzner F (2009). Evolution and male fertility – lessons from
INSL6. Endocrinology 150: 3986–3990.
Ivell R, Heng K, Anand-Ivell R (2014). Insulin-like factor 3 (INSL3)
and the HPG axis in the male. Front Exp Endocrinol 5: 6.
Ivell R, Hunt N, Khan Dawood F, Dawood MY (1989). Expression of
the human relaxin gene in the corpus luteum of the menstrual cycle
and the prostate. Mol Cell Endocrinol 66: 251–255.
Ivell R, Kotula-Balak M, Glynn D, Heng K, Anand-Ivell R (2011).
Relaxin family peptides in the male reproductive system – a critical
appraisal. Mol Hum Reprod 17: 71–84.
Ivell R, Wade JD, Anand-Ivell R (2013). Insulin-like factor 3 (INSL3) as
a biomarker of Leydig cell functional capacity. Biol Reprod 88: 147.
Jensen MS, Anand-Ivell R, Nørgaard-Pedersen B, Jönsson BAG, Bonde
JP, Hougaard DM et al. (2015). Second trimester amniotic ﬂuid DEHP
and DiNP metabolite levels: associations with fetal Leydig cell
function, cryptorchidism and hypospadias. Epidemiology 26: 91–99.
Johansen ML, Anand-Ivell R, Mouritsen A, Hagen CP, Mieritz MG,
Søeborg T et al. (2014). Serum levels of insulin-like factor 3, anti-
Müllerian hormone, inhibin B and testosterone during pubertal
transition in healthy boys: a longitudinal pilot study. Reproduction
147: 529–535.
BJP R Ivell et al.
10 British Journal of Pharmacology (2017) •• ••–••
Kaftanovskaya EM, Huang Z, Barbara AM, De Gendt K, Verhoeven G,
Gorlov IP et al. (2012). Cryptorchidism in mice with an androgen
receptor ablation in gubernaculum testis. Mol Endocrinol 26:
598–607.
Kaftanovskaya EM, Huang Z, Lopez C, Conrad KP, Agoulnik AI
(2015a). Conditional deletion of the relaxin receptor gene in cells of
smooth muscle lineage affects lower reproductive tract in pregnant
mice. Biol Reprod 92: 91.
Kaftanovskaya EM, Lopez C, Ferguson L, Myhr C, Agoulnik AI
(2015b). Genetic ablation of androgen receptor signaling in fetal
Leydig cell lineage affects Leydig cell functions in adult testis. FASEB J
29: 2327–2337.
Kamat AA, Feng S, Bogatcheva NV, Truong A, Bishop CE, Agoulnik AI
(2004). Genetic targeting of relaxin and insulin-like factor 3 receptors
in mice. Endocrinology 145: 4712–4720.
Kato S, Siqin, Minagawa I, Aoshima T, Sagata D, Konishi H et al.
(2010). Evidence for expression of relaxin hormone-receptor system
in the boar testis. J Endocrinol 207: 135–149.
Klonisch T, Bialek J, Radestock Y, Hoang-Vu C, Hombach-Klonisch S
(2007). Relaxin-like ligand-receptor systems are autocrine/paracrine
effectors in tumor cells and modulate cancer progression and tissue
invasiveness. Adv Exp Med Biol 612: 104–118.
Klonisch T, Steger K, Kehlen A, AllenWR, Froehlich C, Kauffold J et al.
(2003). INSL3 ligand-receptor system in the equine testis. Biol Reprod
68: 1975–1981.
Kohsaka T, Takahara H, Sasada H, Kawarasaki T, Bamba K, Masaki J
et al. (1992). Evidence for immunoreactive relaxin in boar seminal
vesicles using combined light and electron microscope
immunocytochemistry. J Reprod Fertil 95: 397–408.
Koskimies P, Virtanen H, Lindstrom M, Kaleva M, Poutanen M,
Huhtaniemi I et al. (2000). A common polymorphism in the human
relaxin-like factor (RLF) gene: no relationship with cryptorchidism.
Pediatr Res 47: 538–541.
Lessing JB, Brenner SH, Colon JM, Ginsburg FW, Schoenfeld C,
Goldsmith LTet al. (1986). Effect of relaxin on human spermatozoa. J
Reprod Med 31: 304–309.
Liu S, Vinall RL, Tepper C, Shi XB, Xue LR, Ma AH et al. (2008).
Inappropriate activation of androgen receptor by relaxin via beta-
catenin pathway. Oncogene 27: 499–505.
Lok S, Johnston DS, Conklin D, Lofton-Day CE, Adams RL, Jelmberg
AC et al. (2000). Identiﬁcation of INSL6, a newmember of the insulin
family that is expressed in the testis of the human and rat. Biol
Reprod 62: 1593–1599.
Luo X, Bathgate RA, Liu YL, Shao XX, Wade JD, Guo ZY (2009).
Recombinant expression of an insulin-like peptide 3 (INSL3)
precursor and its enzymatic conversion to mature human INSL3.
FEBS J 276: 5203–5211.
Luo X, Batgate RA, Zhang WJ, Liu YL, Shao XX, Wade JD et al.
(2010b). Design and recombinant expression of insulin-like peptide 5
precursors and the preparation of mature human INSL5. Amino Acids
39: 1343–1352.
Luo X, Liu YL, Layﬁeld S, Shao XX, Bathgate RA, Wade JD et al.
(2010a). A simple approach for the preparation of mature human
relaxin-3. Peptides 31: 2083–2088.
Mamoulakis C, Georgiou I, Dimitriadis F, Tsounapi P, Giannakis I,
Chatzikyriakidou A et al. (2014). Genetic analysis of the human
Insulin-like 3 gene: absence of mutations in a Greek paediatric cohort
with testicular maldescent. Andrologia 46: 986–996.
Min G, Sherwood OD (1998). Localization of speciﬁc relaxin-binding
cells in the ovary and testis of pigs. Biol Reprod 59: 401–408.
Minagawa I, Fukuda M, Ishige H, Kohriki H, Shibata M, Park EYet al.
(2012). Relaxin-like factor (RLF)/insulin-like peptide 3 (INSL3) is
secreted from testicular Leydig cells as a monomeric protein
comprising three domains B-C-A with full biological activity in boars.
Biochem J 441: 265–273.
Nascimento AR, Pimenta MT, Lucas TF, Royer C, Porto CS, Lazari MF
(2012). Intracellular signaling pathways involved in the relaxin-
induced proliferation of rat Sertoli cells. Eur J Pharmacol 691:
283–291.
Nef S, Parada LF (1999). Cryptorchidism in mice mutant for INSL3.
Nat Genet 22: 295–299.
Neschadim A, Pritzker LB, Pritzker KP, Branch DR, Summerlee AJ,
Trachtenberg J et al. (2014). Relaxin receptor antagonist AT-001
synergizes with docetaxel in androgen-independent prostate
xenografts. Endocr Relat Cancer 21: 459–471.
Overbeek PA, Gorlov IP, Sutherland RW, Houston JB, Harrison WR,
Boettger-Tong HL et al. (2001). A transgenic insertion causing
cryptorchidism in mice. Genesis 30: 26–35.
Pathirana IN, Ashida Y, Kawate N, Tanaka K, Tsuji M, Takahashi M
et al. (2011). Comparison of testosterone and insulin-like peptide 3
secretions in response to human chorionic gonadotropin in cultured
interstitial cells from scrotal and retained testes in dogs. Anim Reprod
Sci 124: 138–144.
PuschW, Balvers M, Ivell R (1996). Molecular cloning and expression
of the relaxin like factor from the mouse testis. Endocrinology 137:
3009-3013. Regul Pept 159: 44–53.
Sagata D, Minagawa I, Kohriki H, Pitia AM, Uera N, Katakura Yet al.
(2015). The insulin-like factor 3 (INSL3)-receptor (RXFP2 network
functions as a germ cell survival/anti-apoptotic factor in boar testes).
Endocrinology 156: 1523–1539.
Samuel CS, Tian H, Zhao L, Amento EP (2003). Relaxin is a key
mediator of prostate growth and male reproductive tract
development. Lab Invest 83: 1055–1067.
Sherwood OD (1994). Relaxin. In: Knobil E, Neill JD (eds). The
Physiology of Reproduction. Raven Press: New York, pp. 861–1009.
Silvertown JD, Neschadim A, Liu HN, Shannon P, Walia JS, Kao JC
et al. (2010). Relaxin-3 and receptors in the human and rhesus brain
and reproductive tissues. Regul Pept 159: 44–53.
Silvertown JD, Ng J, Sato T, Summerlee AJ, Medin JA (2006). H2
relaxin overexpression increases in vivo prostate xenograft tumor
growth and angiogenesis. Int J Cancer 118: 62–73.
Silvertown JD, Symes JC, Neschadim A, Nonaka T, Kao JC, Summerlee
AJ et al. (2007). Analog of H2 relaxin exhibits antagonistic properties
and impairs prostate tumor growth. FASEB J 21: 754–765.
Smith CM, Shen PJ, Ma S, Sutton SW, Gundlach AL (2009).
Veriﬁcation of a relaxin-3 knockout/LacZ reporter mouse as a model
of relaxin-3 deﬁciency. Ann N Y Acad Sci 1160: 259–260.
Soh YM, Tiwan A, Mahendroo M, Conrad KP, Parry LJ (2012). Relaxin
regulates hyaluronan synthesis and aquaporins in the cervix of late
pregnant mice. Endocrinology 153: 6054–6064.
Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ,
Alexander SP et al. (2016). The IUPHAR/BPS Guide to
PHARMACOLOGY in 2016: towards curated quantitative
interactions between 1300 protein targets and 6000 ligands. Nucl
Acids Res 44: D1054–D1068.
Relaxin-like peptides in male reproduction BJP
British Journal of Pharmacology (2017) •• ••–•• 11
Spiess AN, Balvers M, Tena Sempere M, Huhtaniemi I, Parry L, Ivell R
(1999). Structure and expression of the rat relaxin like factor (RLF)
gene. Mol Reprod Dev 54: 319–325.
Teerds KJ, Huhtaniemi IT (2015). Morphological and functional
maturation of Leydig cells: from rodent models to primates. Hum
Reprod Update 21: 310–328.
Thompson VC, Hurtado-Coll A, Turbin D, Fazli L, Lehman ML,
Gleave ME et al. (2010). Relaxin drives Wnt signaling through
upregulation of PCDHY in prostate cancer. Prostate 70: 1134–1145.
Thompson VC, Morris TG, Cochrane DR, Cavanagh J, Wafa LA,
Hamilton T et al. (2006). Relaxin becomes upregulated during prostate
cancer progression to androgen independence and is negatively
regulated by androgens. Prostate 66: 1698–1709.
Tietjens J, Teerlink JR (2016). Serelaxin and acute heart failure. Heart
102: 95–99. Transl Res. 154:1-6
TombocM, Lee PA,MitwallyMF, Schneck FX, Bellinger M,Witchel SF
(2000). Insulin-like 3/relaxin-like factor gene mutations are
associated with cryptorchidism. J Clin Endocrinol Metab 85:
4013–4018.
Valckx SD, De Pauw I, De Neubourg D, Inion I, Berth M, Fransen E
et al. (2012). BMI-related metabolic composition of the follicular ﬂuid
of women undergoing assisted reproductive treatment and the
consequences for oocyte and embryo quality. Hum Reprod 27:
3531–3539.
Vernunft A, Ivell R, Heng K, Anand-Ivell R (2016). The male fetal
biomarker INSL3 reveals substantial hormone exchange between
fetuses in early pig gestation. PLoS One 11: e0157954.
Vinall RL,Mahaffey CM, Davis RR, Luo Z, Gandour-Edwards R, Ghosh
PM et al. (2011). Dual blockade of PKA and NF-κB inhibits H2 relaxin-
mediated castrate-resistant growth of prostate cancer sublines and
induces apoptosis. Horm Cancer 2: 224–238.
Vinall RL, Tepper CG, Shi XB, Xue LA, Gandour-Edwards R, de Vere
White RW (2006). The R273H p53 mutation can facilitate the
androgen-independent growth of LNCaP by a mechanism that
involves H2 relaxin and its cognate receptor LGR7. Oncogene 25:
2082–2093.
Weiss G, Teichman S, Stewart D, Nader D, Wood S, Breining P et al.
(2016). Recombinant human relaxin versus placebo for cervical
ripening: a double-blind randomized trial in pregnant women
scheduled for induction of labour. BMC Pregnancy Childbirth 16:
260.
Wikström AM, Bay K, Hero M, Andersson AM, Dunkel L (2006).
Serum insulin-like factor 3 levels during puberty in healthy boys and
boys with Klinefelter syndrome. J Clin Endocrinol Metab 91:
4705–4708.
Winslow JW, Shih A, Bourell JH, Weiss G, Reed B, Stults JTet al.
(1992). Human seminal relaxin is a product of the same gene as
human luteal relaxin. Endocrinology 130: 2660–2668.
Xiao J, Huang Z, Chen CZ, Agoulnik IU, Southall N, Hu X et al. (2013).
Identiﬁcation and optimization of small-molecule agonists of the
human relaxin hormone receptor RXFP1. Nat Commun 4: 1953.
Yamazawa K, Wada Y, Sasagawa I, Aoki K, Ueoka K, Ogata T (2007).
Mutation and polymorphism analyses of INSL3 and LGR8/GREAT in
62 Japanese patients with cryptorchidism. Horm Res 67: 73–76.
Yao L, Agoulnik AI, Cooke PS, Meling DD, Sherwood OD (2009).
Relative roles of the epithelial and stromal tissue compartment(s) in
mediating the actions of relaxin and estrogen on cell proliferation
and apoptosis in the mouse lower reproductive tract. Ann N Y Acad
Sci 1160: 121–129.
Yegorov S, Bogerd J, Good SV (2014). The relaxin family peptide
receptors and their ligands: new developments and paradigms in the
evolution from jawless ﬁsh to mammals. Gen Comp Endocrinol 209:
93–105.
Yegorov S, Good SV (2012). Using paleogenomics to study the
evolution of gene families: origin and duplication history of the
relaxin family hormones and their receptors. PLoS One 7: e32923.
Yki-Järvinen H, Wahlström T, Seppälä M (1983).
Immunohistochemical demonstration of relaxin in the genital tract
of men. J Reprod Fertil 69: 693–695.
Yoshida T, Kumagai H, Suzuki A, Kobayashi N, Ohkawa S, Odamaki M
et al. (2012). Relaxin ameliorates salt-sensitive hypertension and
renal ﬁbrosis. Nephrol Dial Transplant 27: 2190–2197.
Zarreh-Hoshyari-KhahMR, Bartsch O, Einspanier A, Pohnke Y, Ivell R
(2001). Bioactivity of recombinant pro-relaxin from the marmoset
monkey. Regul Pept 97: 139–146.
Zarreh-Hoshyari-Khah MR, Einspanier A, Ivell R (1999). Differential
splicing and expression of the relaxin like factor gene in reproductive
tissues of the marmoset monkey (Callithrix jacchus). Biol Reprod 60:
445–453.
Zhao L, Roche PJ, Gunnersen JM, Hammond VE, Tregear GW,
Wintour EM et al. (1999). Mice without a functional relaxin gene are
unable to deliver milk to their pups. Endocrinology 140: 445–453.
Zimmermann S, Steding G, Emmen JM, Brinkmann AO, Nayernia K,
Holstein AF et al. (1999). Targeted disruption of the INSL3 gene causes
bilateral cryptorchidism. Mol Endocrinol 13: 681–691.
BJP R Ivell et al.
12 British Journal of Pharmacology (2017) •• ••–••
